Andreas Clemens

9PUBLICATIONS
45CO-AUTHORS
AutoimmunityMedical molecular engineering of nucleic acids and proteinsCancer therapy (excl. chemotherapy and radiation therapy)Neurology and neuromuscular diseasesDisease surveillance
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (9)

|Feb 01, 2023
A root cause analysis to identify the mechanistic drivers of immunogenicity against the anti-VEGF biotherapeutic brolucizumab.

Jeffrey D Kearns, Paul Wassmann, Ufuk Olgac

|Feb 01, 2023
Anti-brolucizumab immune response as one prerequisite for rare retinal vasculitis/retinal vascular occlusion adverse events.

Anette C Karle, Matthias B Wrobel, Stephan Koepke

|Aug 07, 2021
Does real-time artificial intelligence-based visual pathology enhancement of three-dimensional optical coherence tomography scans optimise treatment decision in patients with nAMD? Rationale and design of the RAZORBILL study.

Frank G Holz, Rodrigo Abreu-Gonzalez, Francesco Bandello

|Jul 30, 2021
Effectiveness and safety of ranibizumab in patients with central retinal vein occlusion: results from the real-world, global, LUMINOUS study.

Andrew Lotery, Andreas Clemens, Raman Tuli

|Apr 02, 2021
Fluid as a critical biomarker in neovascular age-related macular degeneration management: literature review and consensus recommendations.

Laurent Kodjikian, Mariacristina Parravano, Andreas Clemens

|Aug 09, 2020
Clinical Impact and Healthcare Resource Utilization Associated with Early versus Late COPD Diagnosis in Patients from UK CPRD Database.

Konstantinos Kostikas, David Price, Florian S Gutzwiller

Pageof 2

Frequent Collaborators

2 joint publications

David Price

2 joint publications

Konstantinos Kostikas

2 joint publications

Tina Rubic-Schneider

2 joint publications

Robert Fogel